Novavax’s Covid-19 vaccine candidate showed strong efficacy against the coronavirus in a large trial that signals a new option is nearing for a global community still desperate for protection against the virus and its variants.

The shot was 90% effective at preventing symptomatic Covid-19 and 100% effective at preventing moderate and severe symptoms, the US-based biotech firm said in a statement on Monday. It was also 93% effective against variants of concern, according to results from a secondary analysis that mostly included cases of the alpha variant predominant in the US..

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.